Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Only the smoking/cardiovascular risk claim is evaluable from the provided label excerpts and it is supported. The remainder of the AI-generated claims are not supported/verified against the supplied label text in the prompt, so overall alignment is only partial.
Category Scores
Accurate Statements
Cigarette smoking increases the risk of serious cardiovascular events from this combination oral contraceptive; the risk increases with age (especially >35) and number of cigarettes smoked.
BOXED WARNING — CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS: “Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked.”
The label indicates increased risk among older women (>35) and smokers.
SECTION 5.1 — Thromboembolic Disorders and Other Vascular Conditions: “The risk is greater among older women (>35 years of age), smokers, ...”
The product is contraindicated in women over 35 who smoke.
SECTION 4 — CONTRAINDICATIONS: “Smoke, if over age 35 [See Boxed Warning and Warnings and Precautions (5.1)]”; SECTION 5.1: “... is contraindicated in women over 35 years of age who smoke ...”
Unsupported Statements
“Levonorgestrel and ethinyl estradiol” is a combined oral contraceptive (COC).
The provided label excerpts in the prompt used for evaluation do not explicitly state this as a COC; other sections (e.g., indications/description) are not included in the supplied text.
“Lupin” indicates the manufacturer brand (a Lupin pharmaceutical product) of a COC.
No manufacturer/brand-label mapping information is provided in the supplied label excerpts.
A COC containing levonorgestrel and ethinyl estradiol contains levonorgestrel (a progestin).
No statement about levonorgestrel being a progestin is included in the supplied label excerpts.
A COC containing levonorgestrel and ethinyl estradiol contains ethinyl estradiol (an estrogen).
No statement about ethinyl estradiol being an estrogen is included in the supplied label excerpts.
Levonorgestrel and ethinyl estradiol work mainly by preventing ovulation.
No mechanism-of-action language (e.g., preventing ovulation) is present in the supplied label excerpts.
Levonorgestrel and ethinyl estradiol work mainly by thickening cervical mucus to reduce the chance of pregnancy.
No mechanism-of-action language regarding cervical mucus is present in the supplied label excerpts.
The most common reason patients use combined levonorgestrel/ethinyl estradiol pills is contraception.
No utilization/usage-frequency information is present in the supplied label excerpts.
Clinicians may prescribe combined levonorgestrel/ethinyl estradiol pills for cycle-related issues such as regulating bleeding.
No label text provided for indications related to cycle control/bleeding regulation.
Combined levonorgestrel/ethinyl estradiol pills are usually taken in a daily cycle.
No dosing schedule language is included in the supplied label excerpts.
Some combined levonorgestrel/ethinyl estradiol pills are taken in a 21-active-pill/7-day-break style regimen.
No regimen-specific description (21/7) is present in the supplied label excerpts.
Some combined levonorgestrel/ethinyl estradiol pills are taken in a 24-active-pill/4-placebo style regimen.
No regimen-specific description (24/4) is present in the supplied label excerpts.
Common side effects ... can include nausea.
No adverse reaction/side effect frequency language is included in the supplied label excerpts.
Common side effects ... can include breast tenderness.
No adverse reaction/side effect language is included in the supplied label excerpts.
Common side effects ... can include spotting between periods early in use.
No adverse reaction/side effect language is included in the supplied label excerpts.
Common side effects ... can include headache.
No adverse reaction/side effect language is included in the supplied label excerpts.
Serious but rarer risks ... include blood clots (venous thromboembolism).
The supplied excerpts focus on smoking/cardiovascular events; no label text provided explicitly stating VTE as a serious but rarer risk.
Serious but rarer risks ... include stroke.
The supplied excerpts do not explicitly state stroke as a “serious but rarer” risk; only smoking/CV events and (in the excerpt) general mention of cerebrovascular events appears, without rarity framing.
The risk ... can be especially higher in people with risk factors such as smoking or certain medical histories.
No label excerpt provided explicitly listing “certain medical histories” as phrased; only smoking and a specific set of conditions (hypertension, dyslipidemia, diabetes, obesity) are shown.
If two ... COC products have the same active ingredients in the same strengths and similar dosing regimen, they are therapeutically equivalent in terms of contraceptive effect.
No FDA label language about therapeutic equivalence/substitution is included in the supplied excerpts.
Differences ... can include tablet strength, dosing schedule (21/7 vs 24/4), and inactive ingredients.
No label excerpt provided comparing brands/regimens or listing inactive ingredient differences.
Differences ... can affect tolerability or bleeding patterns ...
No label excerpt provided linking strength/regimen/inactive ingredients to tolerability/bleeding patterns.
Contradictions
Low
AI Statement
None identified that directly conflict with the supplied label excerpts.
Label Reference
Important Omissions
For a complete label-alignment review of the contraception product, additional label sections would be needed (Indications and Usage; Dosage and Administration; Contraindications beyond smoking; Boxed warning/Warnings beyond CV events; Drug Interactions; Adverse Reactions; Storage).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the smoking/CV risk and related contraindication are supported, many other claims (mechanism, dosing regimens, side effects, and comparative equivalence) are not supported by the label excerpts provided, limiting confidence in safety-related accuracy across the full set of claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims are not verifiable against the supplied FDA label excerpts; only the boxed warning/contraindication regarding smoking and cardiovascular risk is explicitly supported.
Suggested Improvement
Limit statements to label-supported content from the provided label text (or include the missing label sections in the prompt). For non-supported areas (mechanism, dosing regimens, adverse reactions, equivalence), remove or rephrase to avoid unsupported specificity.